Cargando…

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearce, Oliver MT, Läubli, Heinz, Bui, Jack, Varki, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108457/
https://www.ncbi.nlm.nih.gov/pubmed/25083340
http://dx.doi.org/10.4161/onci.29312
_version_ 1782327761234296832
author Pearce, Oliver MT
Läubli, Heinz
Bui, Jack
Varki, Ajit
author_facet Pearce, Oliver MT
Läubli, Heinz
Bui, Jack
Varki, Ajit
author_sort Pearce, Oliver MT
collection PubMed
description We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical implications.
format Online
Article
Text
id pubmed-4108457
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41084572014-07-31 Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Pearce, Oliver MT Läubli, Heinz Bui, Jack Varki, Ajit Oncoimmunology Author's View We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical implications. Landes Bioscience 2014-06-25 /pmc/articles/PMC4108457/ /pubmed/25083340 http://dx.doi.org/10.4161/onci.29312 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Pearce, Oliver MT
Läubli, Heinz
Bui, Jack
Varki, Ajit
Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title_full Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title_fullStr Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title_full_unstemmed Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title_short Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
title_sort hormesis in cancer immunology: does the quantity of an immune reactant matter?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108457/
https://www.ncbi.nlm.nih.gov/pubmed/25083340
http://dx.doi.org/10.4161/onci.29312
work_keys_str_mv AT pearceolivermt hormesisincancerimmunologydoesthequantityofanimmunereactantmatter
AT laubliheinz hormesisincancerimmunologydoesthequantityofanimmunereactantmatter
AT buijack hormesisincancerimmunologydoesthequantityofanimmunereactantmatter
AT varkiajit hormesisincancerimmunologydoesthequantityofanimmunereactantmatter